IDMP as the Global Product Backbone in the AI Era

Across regulatory, clinical, safety, and manufacturing environments, the same medicinal product is often represented in completely different ways. Each function maintains its own identifiers, lifecycle definitions, and operational context. While these systems may work independently, they create significant problems when AI models attempt to connect insights across domains.

This is where understanding the true role of IDMP in the AI era becomes strategically important. Rather than acting solely as a compliance framework, it creates the foundation for a globally consistent product identity that can support AI-ready knowledge structures across the enterprise.

The Fragmentation Problem in Product-Centric AI

Pharmaceutical organisations have historically developed domain-specific representations of medicinal products. Each operational area defines and manages products according to its own priorities, workflows, and regulatory obligations:

• Regulatory systems define authorised products and submission-specific identifiers 
• Clinical systems focus on investigational products and study-related usage 
• Pharmacovigilance systems track adverse events and safety information 
• Manufacturing systems manage formulations, production processes, and batch-level data 

Each perspective is operationally valid within its own context. The challenge emerges when organisations attempt to connect these perspectives through AI-driven analytics, automation, or enterprise-wide intelligence initiatives.

Without a shared product backbone, AI systems encounter conflicting identifiers, inconsistent lifecycle definitions, and disconnected relationships between substances, formulations, and presentations.

As a result, models may process enormous volumes of information while still lacking a coherent understanding of the product itself.

The issue is not data volume. It is structural inconsistency.

IDMP as a Structural Shift

IDMP (Identification of Medicinal Products) introduces a standardised framework for defining medicinal products across their lifecycle. It establishes consistency across four core domains: 

• substance 
• product 
• organisation 
• referential data 

More importantly, leveraging IDMP in the AI era introduces a globally referential product identity that can persist across systems and operational functions.

This represents a major shift from fragmented local records toward a unified product model with explicit relationships and governance.

However, standardisation alone does not create understanding. While IDMP defines what a product is, it does not fully explain how that product evolves over time, why changes occur, or how lifecycle events influence operational interpretation. These dimensions become critical, and must be made explicit, when AI systems are expected to reason across domains rather than simply retrieve information.

Beyond Data, The Missing Layer of Tacit Knowledge

Many critical decisions across the pharmaceutical lifecycle rely on tacit domain expertise.

Safety specialists interpret signals based on historical context and medical judgement. Manufacturing teams understand how variability affects product behaviour in practice. Regulatory experts recognise lifecycle implications that may never appear explicitly within structured datasets.

As a result, organisations may achieve technically correct data models while still lacking operational completeness. AI systems trained on these representations inherit the same limitations, leading to weak reasoning capability, reduced explainability, and growing dependence on implicit assumptions.

The challenge therefore extends beyond standardisation. It requires formalising how experts understand products, states, events, and transitions across the enterprise.

From Structured Data to Structured  Knowledge

To operationalise IDMP in the AI era effectively, organisations must move beyond static representations of product information. A more mature approach requires explicit modelling of:

• product states 
• lifecycle transitions 
• causal relationships 
• contextual dependencies 

For example, a medicinal product may transition from investigational to authorised status, later becoming withdrawn or reformulated. Each transition carries implications that influence how downstream systems interpret the product.

In practical terms, this means mapping regulatory, clinical, safety, and manufacturing systems to IDMP entities, then making those relationships available through a governed semantic layer. That layer does not replace local systems. It gives them a shared product reference model, so identifiers, lifecycle states, and cross-domain relationships can be interpreted consistently across functions. Once this structure is in place, AI systems are better positioned to operate on a traceable product representation rather than reconcile fragmented records after the fact.

Ontology Driven Conceptual Modelling (ODCM) becomes particularly important here because it allows organisations to formalise these relationships in a machine-readable way. Rather than storing isolated records, enterprises begin constructing executable knowledge structures capable of supporting reasoning, traceability, and explainability.

This is the point where IDMP evolves from a regulatory standard into a true enterprise knowledge backbone.

Unified Product Identity Across the Lifecycle 

When IDMP is combined with structured knowledge principles, organisations can establish a persistent product identity that remains consistent across all operational domains.

This creates alignment between:

• regulatory definitions
• clinical applications
• safety monitoring
• manufacturing operations

The result is not simply cleaner data architecture. It is a fundamentally more coherent operating model for AI systems. With lifecycle states and causal relationships explicitly defined, organisations gain stronger traceability, improved semantic consistency, and clearer governance across complex processes.

Most importantly, AI outputs become easier to validate because they can be linked directly to structured product context and lifecycle events.

Why IDMP Matters in the AI Era

AI systems in Life Sciences require more than access to large datasets. They depend on contextual integrity and semantic consistency.

Without a unified product backbone, organisations risk scaling fragmentation rather than intelligence. Models may automate decisions faster but still operate on disconnected interpretations of the same medicinal product. A knowledge-driven IDMP framework changes this dynamic by enabling:

Conclusion 

IDMP represents far more than a compliance initiative. It introduces the structural foundation required for globally consistent product identity in the AI era. When combined with ontology-driven knowledge approaches, IDMP enables organisations to create explainable, traceable, and machine-interpretable product frameworks capable of supporting cross-domain intelligence at scale.

In practice, the challenge is rarely the standard alone. It lies in connecting product data, lifecycle logic, governance, and operational use across regulated environments.

MIGx helps Life Sciences organisations address exactly that by strengthening the context and knowledge structures AI depends on. As AI adoption accelerates, the key question will no longer be whether organisations have enough data. The real differentiator will be whether AI systems can genuinely understand the products they are expected to reason over.